NovoCure Limited (NVCR)
NASDAQ
Market Cap
$1.95B
Sector
Healthcare
Industry
Medical—Instruments & Supplies
Rank in Sector
679 of 809
Rank in Industry
43 of 49
Largest Insider Buys in Sector
NVCR Stock Price History Chart
NVCR Stock Performance
About NovoCure Limited
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Insider Activity of NovoCure Limited
Over the last 12 months, insiders at NovoCure Limited have bought $0 and sold $304,492 worth of NovoCure Limited stock.
On average, over the past 5 years, insiders at NovoCure Limited have bought $433,297 and sold $74.1M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 4,974 shares for transaction amount of $509,539 was made by Danziger Asaf (Chief Executive Officer) on 2021‑11‑26.
List of Insider Buy and Sell Transactions, NovoCure Limited
| 2024-06-04 | Sale | VERNON W ANTHONY | director | 964 0.0009% | $23.89 | $23,033 | -6.68% | |
| 2024-06-04 | Sale | LEUNG GABRIEL | director | 964 0.0009% | $23.89 | $23,025 | -6.68% | |
| 2024-06-04 | Sale | Scannell Timothy J | director | 964 0.0009% | $23.89 | $23,027 | -6.68% | |
| 2024-03-04 | Sale | GROENHUYSEN WILHELMUS CM | Chief Operating Officer | 1,217 0.0011% | $16.01 | $19,484 | -5.11% | |
| 2024-03-04 | Sale | Leonard Frank X | EVP, Pres., Novocure Oncology | 840 0.0008% | $16.01 | $13,448 | -5.11% | |
| 2024-03-01 | Sale | GROENHUYSEN WILHELMUS CM | Chief Operating Officer | 2,107 0.0019% | $16.03 | $33,769 | -3.82% | |
| 2024-03-01 | Sale | Leonard Frank X | EVP, Pres., Novocure Oncology | 1,679 0.0015% | $16.03 | $26,909 | -3.82% | |
| 2024-02-28 | Sale | GROENHUYSEN WILHELMUS CM | Chief Operating Officer | 2,303 0.0022% | $16.14 | $37,177 | -2.43% | |
| 2024-02-28 | Sale | Leonard Frank X | EVP, Pres., Novocure Oncology | 2,078 0.002% | $16.14 | $33,545 | -2.43% | |
| 2023-11-07 | Sale | Shah Pritesh | Chief Growth Officer | 382 0.0004% | $12.65 | $4,832 | +12.66% | |
| 2023-09-01 | Sale | GROENHUYSEN WILHELMUS CM | Chief Operating Officer | 294 0.0003% | $21.82 | $6,414 | -34.41% | |
| 2023-09-01 | Sale | Shah Pritesh | Chief Growth Officer | 273 0.0003% | $21.82 | $5,956 | -34.41% | |
| 2023-09-01 | Sale | Cordova Ashley | Chief Financial Officer | 883 0.0008% | $21.82 | $19,265 | -34.41% | |
| 2023-08-02 | Sale | Cordova Ashley | Chief Financial Officer | 1,144 0.0011% | $30.25 | $34,607 | -50.55% | |
| 2023-03-07 | Sale | Leonard Frank X | President, CNS Cancers US | 8,318 0.0079% | $75.16 | $625,205 | -73.25% | |
| 2023-03-03 | Sale | GROENHUYSEN WILHELMUS CM | Chief Operating Officer | 25,635 0.0236% | $76.16 | $1.95M | -73.53% | |
| 2023-03-03 | Sale | Shah Pritesh | Chief Growth Officer | 21,421 0.0198% | $76.16 | $1.63M | -73.53% | |
| 2023-03-03 | Sale | Cordova Ashley | Chief Financial Officer | 4,730 0.0044% | $76.16 | $360,234 | -73.53% | |
| 2023-03-03 | Sale | Cordova Ashley | Chief Financial Officer | 5,505 0.0051% | $76.16 | $419,258 | -73.53% | |
| 2023-03-03 | Sale | Leonard Frank X | President, CNS Cancers US | 2,059 0.0019% | $77.64 | $159,859 | -73.53% |
Insider Historical Profitability
29.19%
| GROENHUYSEN WILHELMUS CM | Chief Operating Officer | 251235 0.1964% | $18.16 | 0 | 59 | |
| VERNON W ANTHONY | director | 164833 0.1484% | $18.16 | 0 | 2 | |
| Shah Pritesh | Chief Growth Officer | 124511 0.1165% | $18.16 | 1 | 50 | +85.52% |
| Cordova Ashley | Chief Financial Officer | 99650 0.0933% | $18.16 | 0 | 16 | |
| LEUNG GABRIEL | director | 78175 0.0682% | $18.16 | 0 | 38 | |
| Leonard Frank X | President, CNS Cancers US | 160098 0.0508% | $18.16 | 0 | 29 | |
| Scannell Timothy J | director | 2964 0.0028% | $18.16 | 0 | 1 | |
| Perlhagen Gert L. | director | 6125000 5.7317% | $18.16 | 1 | 1 | +171.79% |
| Pomona Capital VII, L.P. | 10 percent owner | 2741925 2.5659% | $18.16 | 0 | 2 | |
| Palti Yoram | Chief Technology Officer | 1041054 0.9742% | $18.16 | 0 | 62 | |
| DOYLE WILLIAM F | Executive Chairman | 551176 0.5158% | $18.16 | 0 | 26 | |
| Ambrogi Michael J. | Chief Operating Officer | 220867 0.2067% | $18.16 | 0 | 46 | |
| Kirson Eilon D. | Chief Science Officer | 109063 0.1021% | $18.16 | 0 | 15 | |
| Burke William Patrick | Chief Human Resources Officer | 66090 0.0618% | $18.16 | 0 | 7 | |
| Longsworth Todd Christopher | General Counsel | 62462 0.0585% | $18.16 | 0 | 18 | |
| Weinberg Uri | Chief Science Officer | 43286 0.0405% | $18.16 | 0 | 5 | |
| Benaim Ely | Chief Medical Officer | 34068 0.0319% | $18.16 | 0 | 20 | |
| MYLOD ROBERT J JR | director | 20000 0.0187% | $18.16 | 1 | 0 | <0.0001% |
| Danziger Asaf | Chief Executive Officer | 13583 0.0127% | $18.16 | 2 | 55 | <0.0001% |
| PHILLIPS CHARLES G III | director | 3359 0.0031% | $18.16 | 0 | 4 | |
| HILLEMAN JERYL L | 2537 0.0024% | $18.16 | 0 | 2 | ||
| Madden Martin J. | director | 384 0.0004% | $18.16 | 0 | 1 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| Fidelity Investments | $251.08M | 14.93 | 16.06M | +0.63% | +$1.58M | 0.02 | |
| The Vanguard Group | $156.67M | 9.32 | 10.02M | +2.71% | +$4.14M | <0.01 | |
| BlackRock | $141.99M | 8.44 | 9.08M | +3.33% | +$4.57M | <0.01 | |
| Capital International Investors | $138.55M | 8.24 | 8.86M | +0.03% | +$34,714.23 | 0.03 | |
| State Street | $52.56M | 3.13 | 3.36M | -12.96% | -$7.83M | <0.01 | |
| T. Rowe Price | $37.18M | 2.21 | 2.38M | +5.58% | +$1.96M | 0.01 | |
| Capital World Investors | $36.08M | 2.15 | 2.31M | -29.56% | -$15.14M | 0.01 | |
| Baillie Gifford Co | $31.11M | 1.85 | 1.99M | -58.88% | -$44.54M | 0.02 | |
| Morgan Stanley | $27.46M | 1.63 | 1.76M | +23.84% | +$5.29M | <0.01 | |
| Geode Capital Management | $25.69M | 1.53 | 1.64M | +3.21% | +$799,934.18 | <0.01 | |
| Nordwand Advisors Llc | $23.68M | 1.41 | 1.51M | 0% | +$0 | 9.22 | |
| Two Sigma Advisers LP | $22.49M | 1.34 | 1.44M | -11.97% | -$3.06M | 0.04 | |
| Two Sigma | $21.71M | 1.29 | 1.39M | -5.54% | -$1.27M | 0.04 | |
| Bank of America | $19.62M | 1.17 | 1.26M | +84.96% | +$9.01M | <0.01 | |
| Millennium Management LLC | $19.12M | 1.14 | 1.22M | +15.51% | +$2.57M | 0.01 | |
| Voloridge Investment Management, LLC | $16.54M | 0.98 | 1.06M | -25.83% | -$5.76M | 0.04 | |
| D. E. Shaw & Co. | $14.91M | 0.89 | 953,912 | -30.13% | -$6.43M | 0.02 | |
| Frontier Capital Management Co | $14.4M | 0.86 | 921,116 | +16.09% | +$2M | 0.14 | |
| Cubist Systematic Strategies | $14.28M | 0.85 | 913,801 | +48.02% | +$4.63M | 0.13 | |
| Credit Suisse | $13.25M | 0.79 | 847,520 | -0.7% | -$93,717.48 | 0.01 | |
| Qube Research & Technologies | $12.35M | 0.73 | 790,360 | +2.14% | +$258,348.27 | 0.02 | |
| Marshall Wace | $12.03M | 0.72 | 769,527 | +121.49% | +$6.6M | 0.02 | |
| Federated Hermes | $10.97M | 0.65 | 702,057 | +13.82% | +$1.33M | 0.03 | |
| Soleus Capital Management, L.P. | $10.87M | 0.65 | 695,759 | +131.15% | +$6.17M | 0.1 | |
| Susquehanna International Group | $9.65M | 0.57 | 617,663 | +155.76% | +$5.88M | 0.01 | |
| Coatue Management | $9.51M | 0.57 | 608,672 | +74.85% | +$4.07M | 0.04 | |
| Jane Street Capital | $8.86M | 0.53 | 566,882 | +18.92% | +$1.41M | 0.01 | |
| Palo Alto Investors Lp | $8.78M | 0.52 | 561,908 | 0% | +$0 | 0.99 | |
| Man Group Plc | $8.5M | 0.51 | 543,824 | +245.53% | +$6.04M | 0.02 | |
| Charles Schwab | $8.3M | 0.49 | 531,055 | -3.75% | -$323,853.58 | <0.01 | |
| C Worldwide Group Holding A S | $8.15M | 0.49 | 521,784 | 0% | +$0 | 0.09 | |
| Northern Trust | $7.78M | 0.46 | 497,788 | +0.62% | +$48,015.36 | <0.01 | |
| RHENMAN & PARTNERS ASSET MANAGEMENT AB | $7.74M | 0.46 | 495,307 | +209.57% | +$5.24M | 0.74 | |
| Jacobs Levy Equity Management | $7.43M | 0.44 | 475,226 | +305.61% | +$5.6M | 0.03 | |
| Balyasny Asset Management Llc | $6.68M | 0.4 | 427,279 | +34.87% | +$1.73M | 0.02 | |
| Citadel Advisors LLC | $6.07M | 0.36 | 388,339 | -42.74% | -$4.53M | <0.01 | |
| Tudor Investment Corp Et Al | $5.71M | 0.34 | 365,421 | +98.21% | +$2.83M | 0.07 | |
| Schonfeld Group | $5.69M | 0.34 | 363,777 | +373.9% | +$4.49M | 0.04 | |
| SG Americas Securities, LLC | $5.62M | 0.33 | 359,518 | +57.28% | +$2.05M | 0.03 | |
| Invus Financial Advisors Llc | $5.48M | 0.33 | 350,884 | 0% | +$0 | 4.36 | |
| UBS | $5.4M | 0.32 | 345,664 | +1,944.87% | +$5.14M | <0.01 | |
| Squarepoint Ops LLC | $5.18M | 0.31 | 331,184 | +368.28% | +$4.07M | 0.02 | |
| Goldman Sachs | $5.16M | 0.31 | 329,904 | +2.8% | +$140,388.67 | <0.01 | |
| Connor Clark & Lunn Investment Management Ltd | $4.91M | 0.29 | 314,377 | -23.25% | -$1.49M | 0.01 | |
| Nuveen | $4.52M | 0.27 | 289,109 | -7.54% | -$368,399.13 | <0.01 | |
| Engineers Gate Manager Lp | $4.42M | 0.26 | 282,837 | -15.01% | -$780,452.73 | 0.11 | |
| Td Asset Management Inc | $4.4M | 0.26 | 281,500 | +5.63% | +$234,450.00 | <0.01 | |
| Renaissance Technologies | $4.37M | 0.26 | 279,575 | +175.78% | +$2.79M | 0.01 | |
| Trexquant Investment LP | $4.35M | 0.26 | 278,338 | +22.98% | +$813,041.35 | 0.06 | |
| BNY Mellon | $4.19M | 0.25 | 267,775 | -14.7% | -$721,137.07 | <0.01 |